India’s Pharma Exports Maintain Steady Growth Amid Global Headwinds

India’s pharmaceutical exports crossed $28 billion (≈₹2.3 lakh crore) during April–February FY26, registering a growth of about 5–6% year-on-year. The performance was driven by strong demand for formulations, vaccines, biologicals and AYUSH products, even as global pricing pressures and supply chain disruptions persisted. Despite challenges, the sector is expected to end FY26 with positive growth in rupee terms, supported by currency movements and steady global demand. What This Means * Pharma remains a resilient export sector despite global uncertainties. * Growth in rupee terms indicates currency support to export earnings. * Strong demand across key categories supports stable industry momentum. Key Things to Watch Going Forward 1. Impact of global pricing pressures on margins. 2. Supply chain stability, especially amid geopolitical tensions. 3. Export diversification beyond traditional markets like the US and Europe. 4. Policy support and regulatory approvals in global markets. Opinion India’s pharma export performance highlights the sector’s structural strength and global competitiveness, even in a challenging external environment. While growth remains moderate, the ability to sustain momentum reflects strong product demand and regulatory compliance across markets. However, dependence on key geographies and exposure to pricing pressure remain risks. Going forward, diversification, innovation and supply chain resilience will be critical for sustaining long-term export growth and strengthening India’s position in the global pharmaceutical landscape. Source: The Hindu No Recommendations